The FY2025 (Dec) proxy of DiaMedica Therapeutics names 18 peer companies for pay. Among DiaMedica Therapeutics and these peers, CEO pay was 2nd highest of 5 and total shareholder return was 2nd highest of 5.
2nd highest of 5in DiaMedica Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
$1.2M$3.3M
2nd highest of 5in DiaMedica Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
$95$15,536
Pay peer group, FY2025 (Dec) proxy
| Fulcrum Therapeutics | ||
| Gossamer Bio | ||
| Lineage Cell Therapeutics | ||
| Galectin Therapeutics | ||
| Acumen Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Alto Neuroscience | Not disclosed | Not disclosed |
| Anavex Life Sciences | Not disclosed | Not disclosed |
| Annovis Bio, Inc. | Not disclosed | Not disclosed |
| Applied Therapeutics, Inc. | Not disclosed | Not disclosed |
| Clene Inc. | Not disclosed | Not disclosed |
| Immunic | Not disclosed | Not disclosed |
| Inozyme Pharma, Inc. | Not disclosed | Not disclosed |
| Medicinova | Not disclosed | Not disclosed |
| Mineralys Therapeutics | Not disclosed | Not disclosed |
| Ovid Therapeutics Inc | Not disclosed | Not disclosed |
| PepGen Inc. | Not disclosed | Not disclosed |
| Tourmaline Bio, Inc. | Not disclosed | Not disclosed |
| Vigil Neuroscience, Inc. | Not disclosed | Not disclosed |
18 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.